Marrone Bio Innovations, Inc. (MBII) Income Statement Analysis

See more : Shanghai Huafon Aluminium Corporation (601702.SS) Income Statement Analysis – Financial Results

Complete financial analysis of Marrone Bio Innovations, Inc. (MBII) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Marrone Bio Innovations, Inc., a leading company in the Agricultural Inputs industry within the Basic Materials sector.

You may be interested

Marrone Bio Innovations, Inc. (MBII)

Industry: Agricultural Inputs

Sector: Basic Materials

Website: https://www.marronebio.com

About Marrone Bio Innovations, Inc.

Marrone Bio Innovations, Inc. discovers, develops, and sells biological products for crop protection, crop health, and crop nutrition. Its products include Emergen, Foramin, Foramin ST, Optima, Takla, Pacesetter, Ympact, UBP, and UBP ST for increasing crop health, yield, and quality; Grandevo, a bioinsecticide that controls sucking and chewing insects through feeding; Haven, a plant health product to reduce sun stress and dehydration; Jet-Ag and Jet-Oxide peroxyacetic acid sanitizers that prevent, suppress, eliminate, and control algae, fungi, and bacterial diseases in agriculture and horticultural industries; and Majestene, a bionematicide to control soil-dwelling nematodes and certain soil borne insects. The company also offers Regalia and Stargus, which protects against fungal and bacterial diseases and enhances yields/quality; Venerate, a bioinsecticide that controls chewing and sucking insects and mites; and Zelto, a bionematicide that protects turf, including golf course fairways and greens, and promotes turf health by enhancing plant and root health. It provides its products directly through sales force, as well as through distributors and other commercial partners. The company formerly known as Marrone Organic Innovations, Inc. Marrone Bio Innovations, Inc. was incorporated in 2006 and is headquartered in Raleigh, North Carolina.

Metric	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Revenue	44.31M	100.00K	29.37M	21.22M	18.17M	14.04M	9.80M	9.14M	14.54M	7.14M	5.25M
Cost of Revenue	17.06M	40.00K	13.26M	10.91M	10.53M	9.52M	9.26M	9.44M	10.74M	4.33M	2.17M
Gross Profit	27.25M	60.00K	16.11M	10.31M	7.64M	4.52M	545.00K	-302.00K	3.81M	2.81M	3.08M
Gross Profit Ratio	61.49%	60.00%	54.86%	48.60%	42.05%	32.19%	5.56%	-3.31%	26.18%	39.31%	58.64%
Research & Development	12.08M	30.00K	14.03M	10.66M	10.82M	9.67M	13.50M	19.28M	17.81M	12.74M	9.41M
General & Administrative	0.00	75.00K	30.07M	19.16M	19.81M	18.51M	26.50M	28.95M	15.02M	0.00	0.00
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	30.57M	75.00K	30.07M	19.16M	19.81M	18.51M	26.50M	28.95M	15.02M	0.00	0.00
Other Expenses	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	10.29M	6.79M
Operating Expenses	42.65M	105.00K	44.10M	29.82M	30.63M	28.18M	40.00M	48.23M	32.83M	23.04M	16.20M
Cost & Expenses	59.71M	145.00K	57.36M	40.72M	41.16M	37.70M	49.26M	57.67M	43.57M	27.37M	18.38M
Interest Income	0.00	0.00	0.00	0.00	1.00K	37.00K	51.00K	59.00K	49.00K	16.00K	22.00K
Interest Expense	1.57M	4.00K	1.47M	2.51M	7.73M	7.30M	4.36M	2.91M	6.00M	2.47M	88.00K
Depreciation & Amortization	4.57M	3.56M	3.15M	1.89M	2.04M	2.24M	3.51M	2.58M	976.00K	613.00K	499.00K
EBITDA	-10.37M	3.51M	-32.53M	-15.82M	-21.15M	-21.53M	-35.86M	-46.17M	-21.52M	-35.72M	-12.59M
EBITDA Ratio	-23.41%	3,509.00%	-110.75%	-74.53%	-116.43%	-153.35%	-365.83%	-505.37%	-147.95%	-500.21%	-239.82%
Operating Income	-14.94M	-17.20M	-27.99M	-19.50M	-23.00M	-23.66M	-39.46M	-48.53M	-29.03M	-23.84M	-13.12M
Operating Income Ratio	-33.71%	-17,195.00%	-95.27%	-91.91%	-126.58%	-168.49%	-402.58%	-531.23%	-199.58%	-333.87%	-249.93%
Total Other Income/Expenses	-1.57M	17.14M	-9.19M	-709.00K	-7.93M	-7.41M	-4.27M	-3.13M	536.00K	-14.96M	-56.00K
Income Before Tax	-16.51M	-53.00K	-37.18M	-20.21M	-30.93M	-31.07M	-43.73M	-51.66M	-28.49M	-38.79M	-13.18M
Income Before Tax Ratio	-37.26%	-53.00%	-126.56%	-95.25%	-170.23%	-221.27%	-446.16%	-565.44%	-195.89%	-543.33%	-251.00%
Income Tax Expense	45.00K	17.15M	15.00K	1.80M	-201.00K	-109.00K	92.00K	-219.00K	6.53M	-12.49M	32.00K
Net Income	-16.55M	-53.00K	-37.18M	-20.21M	-30.93M	-31.07M	-43.73M	-51.66M	-28.49M	-38.79M	-13.18M
Net Income Ratio	-37.36%	-53.00%	-126.56%	-95.25%	-170.23%	-221.27%	-446.16%	-565.44%	-195.89%	-543.33%	-251.00%
EPS	-0.09	0.00	-0.32	-0.20	-1.06	-1.26	-1.79	-2.32	-3.26	-2.12	-0.72
EPS Diluted	-0.09	0.00	-0.32	-0.20	-1.06	-1.26	-1.79	-2.32	-3.20	-2.12	-0.72
Weighted Avg Shares Out	174.83M	148.89M	117.98M	101.25M	29.24M	24.62M	24.47M	22.31M	8.73M	18.27M	18.27M
Weighted Avg Shares Out (Dil)	174.83M	148.89M	117.98M	101.25M	29.24M	24.62M	24.47M	22.31M	8.91M	18.27M	18.27M

Bioceres Crop Solutions Completes Merger With Marrone Bio, Creating a Global Leader in Sustainable Agricultural Solutions

July 12, 2022businesswire.com

ROSARIO, Argentina--(BUSINESS WIRE)--Bioceres Crop Solutions completes merger with Madrone Bio, creating a global leader in sustainable agricultural solutions

Marrone Bio Innovations, Inc. Shareholders Approve Merger Agreement with Bioceres Crop Solutions Corp.

July 11, 2022globenewswire.com

RALEIGH, N.C., July 11, 2022 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII) (MBI) announced that during a special shareholder meeting held on July 8, 2022, its shareholders approved a proposal to adopt the previously announced Agreement and Plan...

Marrone Bio's (MBII) Earnings and Revenues Miss Estimates in Q1

May 17, 2022zacks.com

Marrone Bio (MBII) witnessed increased sales of row crop products in the first quarter, offset by lower sales into specialty crop markets.

Marrone Bio Innovations, Inc. (MBII) CEO Kevin Helash on Q1 2022 Results - Earnings Call Transcript

May 11, 2022seekingalpha.com

Marrone Bio Innovations, Inc. (NASDAQ:MBII ) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Kevin Helash – Chief Executive Officer Linda Moore – Chief Legal Officer LaDon Johnson – Interim Chief Financial Officer Matti Tiainen...

Marrone Bio Innovations, Inc. (MBII) Reports Q1 Loss, Lags Revenue Estimates

May 11, 2022zacks.com

Marrone Bio Innovations, Inc. (MBII) delivered earnings and revenue surprises of -300% and 8.29%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Marrone Bio Innovations, Inc. Reports First-Quarter 2022 Financial Results

May 11, 2022globenewswire.com

RALEIGH, N.C., May 11, 2022 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII), an international leader in sustainable bioprotection and plant health solutions, has provided its financial results for the first quarter ended March 31, 2022. Key results include:

MARRONE BIO INVESTOR ALERT - Kuznicki Law PLLC Investigates Proposed Sale of Marrone Bio Innovations, Inc. - MBII

May 4, 2022businesswire.com

CEDARHURST, N.Y.--(BUSINESS WIRE)--Kuznicki Law PLLC is investigating the proposed sale of Marrone Bio Innovations, Inc. (NasdaqCM: MBII) to Bioceres Crop Solutions Corp. (NasdaqGS: BIOX). Under the terms of the proposed transaction, shareholders of Marrone will receive only 0.088 shares of...

MARRONE BIO INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Marrone Bio Innovations, Inc. - MBII

April 27, 2022businesswire.com

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Marrone Bio Innovations, Inc. (NasdaqCM: MBII) to Bioceres Crop Solutions Corp....

Marrone Bio Innovations, Inc. (MBII) Reports Q4 Loss, Tops Revenue Estimates

March 28, 2022zacks.com

Marrone Bio Innovations, Inc. (MBII) delivered earnings and revenue surprises of 0% and 3.85%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?